Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Drug ChannelsJoin Dr.Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Drug Channels Join Dr. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisNext: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
